HC Wainwright Has Pessimistic Outlook of VNDA Q3 Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Research analysts at HC Wainwright cut their Q3 2026 earnings estimates for Vanda Pharmaceuticals in a research report issued to clients and investors on Monday, August 10th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings of ($0.61) per share for the quarter, down from their prior estimate of ($0.36). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($2.65) per share. HC Wainwright also issued estimates for Vanda Pharmaceuticals’ Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($3.03) EPS, Q1 2027 earnings at ($0.41) EPS, Q2 2027 earnings at ($0.24) EPS, Q3 2027 earnings at ($0.18) EPS, Q4 2027 earnings at ($0.11) EPS and FY2027 earnings at ($0.94) EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). Vanda Pharmaceuticals had a negative return on equity of 49.81% and a negative net margin of 127.41%.The business had revenue of $50.53 million for the quarter, compared to analyst estimates of $61.92 million.

Other analysts have also recently issued reports about the company. B. Riley Financial reiterated a “buy” rating and issued a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday. Wall Street Zen cut Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.70.

Vanda Pharmaceuticals Stock Performance

NASDAQ:VNDA opened at $4.93 on Wednesday. Vanda Pharmaceuticals has a 52 week low of $4.17 and a 52 week high of $9.94. The company has a fifty day simple moving average of $5.73 and a two-hundred day simple moving average of $6.71. The company has a quick ratio of 1.60, a current ratio of 1.61 and a debt-to-equity ratio of 0.01. The company has a market cap of $298.07 million, a price-to-earnings ratio of -1.06 and a beta of 0.64.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Torren Management LLC purchased a new stake in shares of Vanda Pharmaceuticals in the 4th quarter valued at approximately $25,000. Russell Investments Group Ltd. lifted its position in shares of Vanda Pharmaceuticals by 456.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 5,328 shares during the last quarter. Allworth Financial LP purchased a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter worth $43,000. Quarry LP purchased a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth $53,000. Finally, Cerity Partners LLC acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth $69,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Key Stories Impacting Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Analysts retain bullish ratings: HC Wainwright maintained a Buy rating and a $20 price target, while B. Riley Financial reiterated its Buy recommendation. These targets imply substantial potential upside from VNDA’s recent $4.93 level. B. Riley Financial Reiterates Buy Rating for Vanda Pharmaceuticals
• Positive Sentiment: Psoriasis pipeline remains an area of investor interest: Vanda was included among psoriasis drug companies to watch during Psoriasis Awareness Month, highlighting potential opportunities from its development programs. Psoriasis Drug Stocks to Watch
• Neutral Sentiment: Short-interest data provides no meaningful signal: Reported short interest was zero shares, with a zero-day days-to-cover ratio. The figures suggest little measurable short-selling activity, but the reported percentage change is not meaningful because the comparison balance was also zero.
• Negative Sentiment: HC Wainwright significantly lowered its earnings outlook: The firm cut its FY2026 EPS estimate to -$3.03 from -$1.98 and its FY2027 forecast to -$0.94 from -$0.36. Quarterly estimates were also reduced, including Q3 2026 to -$0.61 and Q4 2026 to -$0.57. The revisions point to deeper and more prolonged losses than previously expected.
• Negative Sentiment: B. Riley reduced its price target: Although the firm kept its Buy rating, it lowered the target to $12 from $17, signaling less confidence in near-term valuation. The estimate cuts add to concerns following Vanda’s recent quarterly loss and revenue miss.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.